Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$23.41 USD
+0.47 (2.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $23.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Beam Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 378 | 61 | 52 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 378 | 61 | 52 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 554 | 399 | 444 | 133 | 75 |
Income After Depreciation & Amortization | -176 | -338 | -392 | -133 | -75 |
Non-Operating Income | 45 | 78 | 22 | -62 | -3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -131 | -260 | -371 | -195 | -78 |
Income Taxes | 1 | 3 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | -26 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -133 | -289 | -371 | -195 | -78 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -133 | -289 | -371 | -195 | -78 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -186 | -334 | -385 | -128 | -73 |
Depreciation & Amortization (Cash Flow) | -10 | 5 | 7 | 5 | 3 |
Income After Depreciation & Amortization | -176 | -338 | -392 | -133 | -75 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 77.15 | 70.02 | 64.23 | 46.73 | 6.48 |
Diluted EPS Before Non-Recurring Items | -1.72 | -4.13 | -6.05 | -2.83 | -14.05 |
Diluted Net EPS (GAAP) | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 |
Fiscal Year end for Beam Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 11.77 | 7.41 | 316.19 | 17.19 | 20.12 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 11.77 | 7.41 | 316.19 | 17.19 | 20.12 |
SG&A, R&D, and Dept/Amort Expenses | 116.67 | 111.54 | 183.34 | 125.46 | 122.27 |
Income After SG&A, R&D, and Dept/Amort Expenses | -104.90 | -104.13 | 132.85 | -108.27 | -102.15 |
Non-Operating Income | 13.88 | 5.46 | 11.31 | 12.18 | 19.37 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -91.01 | -98.67 | 144.16 | -96.09 | -82.78 |
Income Taxes | 0.04 | 0.00 | 1.37 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -91.05 | -98.67 | 142.80 | -96.09 | -82.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -91.05 | -98.67 | 142.80 | -96.09 | -82.78 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 82.31 | 81.70 | 82.70 | 79.03 | 76.34 |
Diluted EPS Before Non-Recurring Items | -1.11 | -1.21 | 1.73 | -1.22 | -1.08 |
Diluted Net EPS (GAAP) | -1.11 | -1.21 | 1.91 | -1.22 | -1.08 |